According to MHT, BioAnalytix LLC, a spin-off from the Barnett Institute of Chemical and Biological Analysis, raised seed funding of $858,000 from 11 investors, according to a federal filing.
The company analyzes and characterizes large-molecular biologic drugs and biosimilars Kirtland Poss, co-founder and CEO of BioAnalytix, said that the company was founded by itself and three others in recent months: Robert Garnick, consultant with Lone Mountain Biotechnology and Medical Devices Inc. In Las Vegas; Barry Karger, director of the Barnett Institute; and Billy Wu, senior analyst at Barnett and formerly Genentech.
Please note that this piece of work originally appeared in English at https://www.vcnewsdaily.com/BioAnalytix/venture-funding.php. As Investocracy aims to bring global startup news and updates in both English and Japanese to you, it’s important that we attribute original source to you. If you have any questions/concerns please write to us at firstname.lastname@example.org